LON:HIKHikma Pharmaceuticals Share Price, Forecast & News

Hikma Pharmaceuticals' stock was trading at GBX 1,828.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, HIK shares have increased by 15.1% and is now trading at GBX 2,105. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Hikma Pharmaceuticals.

Hikma Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 7th 2020. View our earnings forecast for Hikma Pharmaceuticals.

Hikma Pharmaceuticals declared a dividend on Thursday, February 27th. Investors of record on Thursday, March 19th will be given a dividend of GBX 0.30 per share on Thursday, May 7th. This represents a dividend yield of 1.22%. The ex-dividend date is Thursday, March 19th. This is a boost from Hikma Pharmaceuticals's previous dividend of GBX 0.14. The official announcement can be viewed at this link. View Hikma Pharmaceuticals' dividend history.

8 brokers have issued 12 month price objectives for Hikma Pharmaceuticals' shares. Their forecasts range from GBX 2,200 to GBX 2,600. On average, they expect Hikma Pharmaceuticals' share price to reach GBX 2,410 in the next year. This suggests a possible upside of 14.5% from the stock's current price. View analysts' price targets for Hikma Pharmaceuticals.

News articles about HIK stock have been trending somewhat negative on Saturday, according to InfoTrie. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Hikma Pharmaceuticals earned a coverage optimism score of -1.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Hikma Pharmaceuticals.

Some companies that are related to Hikma Pharmaceuticals include Merck KGaA (MRK), Bausch Health Companies (BHC), Canopy Growth (WEED), Evotec (EVT), Aurora Cannabis (ACB), Aphria (APHA), Knight Therapeutics (GUD), Ecofibre (EOF), HLS Therapeutics (HLS), Hexo (HEXO), OrganiGram (OGI), HEXO (HEXO), Next Science (NXS), Amryt Pharma (AMYT) and ICC Labs (ICC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC).

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

Shares of HIK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

One share of HIK stock can currently be purchased for approximately GBX 2,105.

Hikma Pharmaceuticals has a market capitalization of £4.85 billion and generates £2.21 billion in revenue each year. Hikma Pharmaceuticals employs 8,400 workers across the globe.

The official website for Hikma Pharmaceuticals is www.hikma.com.

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.